The PennZone

PITTSBURGH, Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J. Coury, Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same date to review the quarterly results and provide an update on the company's February 28 Investor Event.

More on The PennZone

• Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
• Mud Morganfield Bares His Soul on 7" Single, 'Deep Gospel'
• Allstream Energy Partners, SEO Experts in Oil and Gas, Awarded Gas Processing OEM Agreement
• Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
• Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ

Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800.225.9448 or 203.518.9708 for international callers (Conference ID: VTRSQ322).  A replay of the webcast also will be available on the website.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.

More on The PennZone

• Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
• Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
• New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
• Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)
• Affordable Braces in Allentown Made Accessible Through Exeter Smiles' Flexible Payment Options

SOURCE Viatris Inc.

---

Show All News | Disclaimer | Report Violation